Revolutionizing the Market Insight Report offerings valuable across the product lifecycle

Rare/Orphan Disease
Oncology Indications
Non-Oncology Indications

Offer best-in-industry knowledge solutions & insights to transform the healthcare world

Rare/Orphan Disease
Oncology Indications
Non-Oncology Indications

Enable clients to unlock the value potential for their assets

Rare/Orphan Disease
Oncology Indications
Non-Oncology Indications

Cutting edge solution, robust analytics, and valuable insights empower evidence-based decision-making

Rare/Orphan Disease
Oncology Indications
Non-Oncology Indications

Our Pillars

What’s new

Reports and Insights

All Reports
June 25, 2025

Market Outlook and Forecast

Moderate to Severe Eosinophilic Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Moderate to Severe Eosinophilic Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Eosinophilic Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

June 8, 2025

Market Outlook and Forecast

Mycobacterium Abscessus Pulmonary Disease (MAPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Mycobacterium Abscessus Pulmonary Disease (MAPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mycobacterium Abscessus Pulmonary Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

June 16, 2025

Market Outlook and Forecast

Mycobacterium Abscessus Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Mycobacterium Abscessus Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mycobacterium Abscessus Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

June 23, 2025

Market Outlook and Forecast

Eosinophilic Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “Eosinophilic Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

June 19, 2025

Market Outlook and Forecast

T-Cell Acute Lymphoblastic Leukemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “T-Cell Acute Lymphoblastic Leukemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential T-Cell Acute Lymphoblastic Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

June 10, 2025

Market Outlook and Forecast

ROSAH Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Thelansis’s “ROSAH Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ROSAH Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

0+

Years Experience

0+

Experts

0+

Physicians in Panel

0+

Payers in Panel

0

Global Delivery Centers

0

Delivered Market Outlook Reports in 2024

Client Reviews

Hear from happy customers about their experience working with us.

“Support on current drug utilizations and benchmarking of emerging therapy, greatly helped us in narrowing down on patient share estimations for internal calculations ״

Santen PharmaDirector

“Patient share for approved therapies are estimated perfectly. Indeed it's great pieces of work. I liked the way segmentation was shown and patient flow was discussed״

Vicore PharmaDirector

“Happy to read the market insight report, really informative and applied to build marketing strategy״

NewronDirector

“This is the first time I worked with Thelansis, I could say the team is truly professional, Cheers guys ״

SanquinDirector

“ We want to congratulate team Thelansis for their continuous support during this tough time ״

WEX TherapeuticsDirector

"We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "

Reata PharmaceuticalsVice President

" We are really fortunate to interact with Thelansis' Forecasting team, well seasoned professionals who understand what's the actual need "

Stemline TherapeuticsVice President- Marketing

"Some great piece of patient based forecast model; and market assumptions. Tying up beautifully with the payer's insights "

CamurusDirector

"Liked the way the outcome was structured. Regulatory assessment was spot-on. Country-wise regulatory scenarios were gold to us at this point"

Asarina PharmaDirector

"Satisfied with the companies core competency around Clinical Trial Outcome analysi"

Acadia PharmaceuticalsDirector

Need customize support?

Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

Ask for a demo